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Randomness and uncertainty are two major problems one faces while modeling nonlinear dynamics of

molecular systems. Stochastic and fuzzy methods are used to cope with these problems, but there is no consensus among
researchers regarding which method should be used when. This is because the areas of applications of these methods
are overlapping with differences in opinions. In the present work, we demonstrate how to use stochastic Petri nets with
fuzzy parameters to manage random timing of biomolecular events and deal with the uncertainty of reaction rates in
biological networks. The approach is demonstrated through a case study of simulation-based prediction of efficient drug
combinations for spinal muscular atrophy, for which we obtained very promising results. The feasibility of the approach is
assessed through statistical analysis of deterministic, pure stochastic and fuzzy stochastic simulation results. Statistical
analysis reveals that all three models produce significantly different results which, when coupled with the fact that fuzzy
stochastic model provides the closest approximation of underlying biological network, successfully coping not only with
randomness but also uncertainty, suggests that fuzzy stochastic model is the most appropriate choice for the present case
study. The proposed approach can be adapted or extended to other biological networks.
Key words: Stochastic Petri nets, fuzzy logic, quantitative modelling, spinal muscular atrophy

1. Introduction
Quantitative modelling of biological networks has experienced renaissance for the past two decades. Quantitative description of molecular interactions in a complex biomolecular system is essential not only to understand
the structure and properties of the system, but also to identify key molecular targets driving major biomolecular processes within this system. Such molecular targets can then be used to predict novel drugs or drug
combinations in line with target-based drug discovery which has developed into an area of intense research. It
is worth to mention that such a model is expected to reproduce the dynamic behavior of the system correctly.
The important stages of quantitative modelling are (i) determination of the underlying biological network based
on rigorous study of the biological databases and literature, (ii) development of the model using methods and
techniques provided by computer science and/or model engineering, (iii) computational validation of the model
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based on known wet lab results, (iv) computer simulations aimed at identification of drugs or beneficial drug
combinations that would play prominent role in the treatment of a disease.
Molecular interactions are characterized by a high degree of randomness and uncertainty. Despite the
fact that randomness and uncertainty are both permissible within the same scope, these concepts essentially
differ from one another. Randomness in biological networks may arise due to low molecular density, intrinsic
random nature of phenomena, and noise in an experiment. An individual molecular event is subject to stochastic
time delays as it takes place whenever the event conditions (availability of substrates, desired level of energy,
temperature and pressure, etc.) are present, but not according to a predefined order. Stochastic nature of
molecular interactions can be represented and analyzed using the Chapman–Kolmogorov equation [1], stochastic
differential equations [2], the Gibson–Bruck algorithm [3], stochastic Pi-calculus [4], the Gillespie algorithm [5],
stochastic process algebra [6], and stochastic Petri nets (SPNs) [7]. Expressive capabilities of the SPNs coupled
with existing powerful analysis tools make SPN modeling approach an indispensable choice in the stochastic
analysis of the biological systems.
It is quite regular that, identical wet lab experiments result in different observations at each time due to
the inexactness of measurements and other technical noise. For instance, genetically identical cells even within
the same tissue often exhibit different levels of gene expression, protein production, and different rates for
biological phenomena. Usually, we deal with imprecise and incomplete knowledge about reaction rates which
are often expressed by qualitative descriptions of parameters such as “is almost disrupted”or “occurs faster
than”. Fuzzy logic allows modelling reaction effects which can be derived from qualitative knowledge.
Mutation in the Survival Motor Neuron 1 (SMN1) gene leads to the absence or insufficient production
of survival motor neuron (SMN) protein, which in turn causes spinal muscular atrophy (SMA), a motor neuron
disease. In humans, there is a second copy of the gene, namely SMN2, which has the required genetic information
to alleviate the disease. However, SMN2 fails to compensate for the loss of SMN1 because it results in only
10%–15% of the full length protein, while its 85%–90% present dysfunctional SMN ∆7 protein. Various drug
candidates have been proposed as potential means of treating SMA or decreasing its severity by increasing SMN
levels produced by SMN2. Increase in concentration of biological component is measured in folds, which is a
ratio of current and nominal concentrations. These drug candidates provide 1.3- to 5-fold increase of SMN,
which is not sufficient to cure SMA. In the present research, we explore the intermolecular interactions in SMN
production network to predict the most efficient drug combinations which can result in maximum SMN levels
from SMN2. Based on this motivation, we use SPNs with fuzzy parameters to develop a quantitative model of
SMN production network, validate the model using biological data, and perform fuzzy stochastic simulations
to predict drug combinations leading to the highest levels of SMN produced from SMN2. Simulation results
allowed us to identify optimal combinations of drug candidates which can increase SMN concentration up to
149.9-folds over the control group, though this number for known drug candidates does not exceed 5-folds.
This paper has the following structure. In the following section, we outline the materials and methods,
briefly reviewing key work to date, introducing SPNs with fuzzy parameters, and discussing biological context.
In the next section, we provide results, describing the model of SMN production network, its validation through
existing empirical data, simulation results, their analysis and comparison of deterministic, pure stochastic, and
fuzzy stochastic models. The paper ends with a discussion and outlook regarding further work.
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2. Materials and methods
2.1. Related work
SPNs bring together modeling power of regular Petri nets and results in stochastic molecular dynamics obtained
by Gillespie [5]. SPNs can represent and analyze both the structure and stochastic dynamics of biological
systems and therefore have attracted much of the attention since late 1990s. Over the last two decades, much
research has been published on applications of SPNs in biological systems. Goss et al. [8] used SPNs to
model plasmid ColE1 replication. To our knowledge, this is the first account on the use of SPNs for modeling
biological systems. Srivastava et al. [9] demonstrated with the example of Escherichia coli stress circuit, the
appropriateness and conceptual simplicity of modeling gene regulatory networks using SPNs. Bahi-Jaber et al.
[10] exploited colored SPNs to develop and investigate complex stochastic epidemic models. Marwan et al. [11]
demonstrated on example of Physarum polycephalum how hierarchical-structured SPNs can be used to represent
the gene regulatory pathway controlling the commitment and sporulation. Mura et al. [12] applied SPNs to
model cell cycle in yeast. Lamprecht et al. [13] used SPNs to create model of Ca2+ release sites composed of
a number of intracellular channels that have stochastic behavior, and Marwan et al. [14] investigated enteric
bacteria phosphate regulation by using SPNs, while Castaldi et al. [15] developed SPN model of the tissue
factor-induced coagulation cascade. Liu et al. [16] used fuzzy SPNs to create a yeast polarization model,
and Bashirov et al. [17] presented stochastic simulation-based validation and analysis of the p16-mediated
pathway, the disruption of which is among major causes of human cancers. Software tools used to conduct
the above research include Snoopy [18], Möbius [19] and GreatSPN [20], while https://www.informatik.unihamburg.de/cgi-bin/TGI/tools/ collects links to 23 Petri net tools and software supporting SPNs.
Knowledge on kinetic parameters is vague than crisp and therefore is usually represented by natural
language-based qualitative knowledge. Fuzzy logic is proved to be an efficient approach to deal with vagueness
in biological models. Below we review the biological models developed using of Petri nets with fuzzy sets.
Sokhansanj et al. [21] developed an algorithm that allows the creation of a model of intergenetic interactions
based on the theory of fuzzy sets, which was later modified by Gintrowski [22] to reduce the search time in gene
network. Hamed [23] introduced a quantitative model of a gene network in which imperfect kinetic data was
reproduced in terms of fuzzy logic. Mehraei [24] exploited fuzzy stochastic hybrid Petri nets in modelling of
mood disorder treatment. Liu et al. [16] combined SPNs and fuzzy logic in order to create a quantitative model
of biological systems in which reaction rates are associated with fuzzy numbers. Bordon et al. [25] demonstrated
how fuzzy logic and Petri nets can be used to deal with unknown or imprecise data arising from gene regulatory
processes, and Liu et al. [26] represented interactions among genes with fuzzy rules implementing colored fuzzy
Petri nets. Most of Petri net software and tools cannot handle fuzzy numbers. Once SPN model is created
using one of the Petri net software such as Snoopy [18], it can be further fuzzified using MATLAB or similar
software.
So far, there is no widespread evidence of the applications of both SPNs and fuzzy logic in biological
models. To the best of our knowledge, the present paper is one of the first attempts [16, 25] to associate fuzzy
numbers with reaction rates and concentrations in an SPN model of a biological network. Moreover, this work
is the first account on the use of SPNs with fuzzy parameters in a target-based drug combination discovery.
2.2. Stochastic Petri nets with fuzzy parameters
For the last three decades, Petri nets have been extensively exploited for modelling biological systems. Below we
briefly summarize the relationship between Petri net components and biological objects. A Petri net, sometimes
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referred to as basic Petri net, is formally defined as 5-tuple P N =< P, T, F, f, M0 > such as
• P = {p1 , . . . pn } is a set of the places,
• T = {t1 , . . . tm } is a set of the transitions,
• F ⊆ (P × T ) ∪ (T × P ) is a set of directed arcs,
• f : F → N+ is a function that assigns a weight to each arc a ∈ F ,
• M0 : P → N0 is the initial marking,
where P ∩ T = ∅ .
While modelling biological systems with Petri nets, places, and transitions represent biological components (gene, protein, etc.) and biological processes (transcription, translation, binding, etc.), respectively, arcs
determine the flow of biochemical reactions. The concentration of biological components changes according to
the arc weights. The initial marking determines the initial state of a biological system being modelled.
2.2.1. Stochastic Petri nets
Basic Petri nets provide powerful modeling technique for learning logic behavior of dynamic systems but not
their quantitative behavior. This is because basic Petri nets are not complete enough for modeling dynamic
systems in which system activities are changing over time. In real world, however, almost every action is time
dependent. There are many possible ways to associate time to basic Petri nets. Time Petri nets are timedependent deterministic Petri nets that are gained wide application in scientific and engineering domains. In a
time Petri net, each transition is associated with deterministic firing time interval so that enabled transitions
may fire only during specified time intervals. The transitions must fire the latest at the end of their intervals if
they are still enabled then. At any given moment, only one transition may fire. This firing does not take time.
Occurrence of a biochemical reaction is an entirely stochastic process which depends on the availability
of the substrates and the presence of other conditions. Therefore, a regular Petri net as described above is not
sufficient to create quantitative models of biological systems to the desired details of comprehension. In the
present work, we use SPNs to associate random time delays with occurrences of transitions. In an SPN model,
time from the enabling of a transition to its next occurrence is a random variable with negative exponential
probability distribution function.
F (t) = 1 − e−λt if t ≥ 0 and F (t) = 0 otherwise, λ > 0.
We develop an SPN model of SMN production network and perform 38,000 stochastic replications for
each combination of drug candidates, which are further averaged to obtain a reliable estimation of simulationbased behavior of SMN production network. This allows us to reach in stochastic simulations to a confidence
level of 95% with the accuracy of 10−2 .
2.2.2. Fuzzy logic
Fuzzy logic proposed by Zadeh [27] provides a systematic framework for dealing with uncertainty, imprecision,
and vagueness of kinetic parameters. In this theory, a fuzzy set ζe defined on a universal set X is determined
by its membership function µζe : X → [0, 1], which assigns to each element x ∈ X a real value µζe in [0, 1].
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Fuzzy numbers are the fuzzy sets that are normalized and convex. A fuzzy number can be represented in
different formats such as triangular and trapezoidal. We associate triangular fuzzy numbers with reaction rates
and concentrations. A triangular fuzzy number ζe is defined by three numbers a < b < c where [a, b] is the
base of the triangle and x = c is its vertex. Triangular fuzzy number represented in Figure 1 is monotonically
increasing in interval [a,b], and it is monotonically decreasing in interval [b,c]. A triangular fuzzy number
µζe = (a, b, c), a ≤ b ≤ c is formally defined as follows:

ζe =


0,


 x−a




b−a ,
c−x
c−b ,

0,

if
if
if
if

x ≤ a;
a ≤ x ≤ b;
b ≤ x ≤ c;
x ≥ c.

1

x
0

a

b

c

Figure 1. A triangular fuzzy number ζe.

2.3. Biological context
SMA is the leading genetic cause of infant mortality and the second most common fatal autosomal recessive
disorder after cystic fibrosis. The disease affects 1 in 6000–10,000 newborns. The disease is caused by the
deletion of or mutations in the SMN1 gene. Several approaches have been suggested for treating SMA or
decreasing its severity. These approaches can be classified into four approaches, namely, promoting SMN2
transcription through use of histone deacetylase (HDAC) inhibitors, increasing correct splicing of the SMN2
transcript, upregulating promoter activity of SMN2, increasing SMN2 activity through deoxyribonucleic acid
(DNA) demethylation. In what follows, we briefly review existing approaches. The present work combines all
these approaches to account for the total efficacy of various combinations of potential drugs with existing qPCR
data.
2.3.1. Inhibition of the inhibitor
One way to treat SMA is through the inhibition of HDAC activity that is known to suppress the SMN2
expression. We have found that ValProic Acid (VPA), TrichoStatin A (TSA), Dacinostat, and Resveratrol are
the only HDAC inhibitors reported so far in the biological literature for which there are available qPCR and
protein data on increased levels of SMN produced from SMN2.
Brichta et al. reported on 2- to 4-fold increase of SMN levels in fibroblast cultures derived from SMA
patients treated with 0.5-–500 µ M of VPA. VPA is a well-known drug that has regularly used in a long-term
epilepsy treatment, and has recently been shown to yield therapeutic effects in mood disorders and migraine.
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Avila et al. [28] observed that TSA treatment in SMA model mice results in 1.5- to 2-fold increase of SMN
protein levels in the brain, liver, and spinal cord. Dayangaç-Erden et al. [29] noticed on 1.3-fold increase in
SMN protein levels relative to untreated cultures after treatment with 100 µ M of Resveratrol.
2.3.2. Regulating pre-mRNA splicing
While all the genetic information for functional SMN protein is present in the SMN2 gene, a translationally silent
C to T change in SMN2 exon 7 results in exon skipping. This causes the production of a truncated, unstable
SMN ∆7 protein. Hastings et al. [30] showed that treatment with the tetracycline derivative PTMK-SMA1 in
type III SMA mice promotes the inclusion of exon 7 into SMN2 mRNA during the splicing step, eliciting nearly
5-fold increase in SMN protein concentrations compared to untreated animals. Hastings et al. [30] reported that
PTMK-SMA1 is the only chemical identified to date that has been demonstrated to alter splicing by directly
targeting the splicing reaction to promote a specific splicing pathway.
2.3.3. Upregulating promoter activity
Jarecki [31] suggested to enhance SMN transcription arising from SMN2 through the manipulation of the
SMN2 promoter activity. It is reported in the same study that treatment with Indole in patient-derived cells
demonstrates direct effect on SMN2 promoter activity, increasing SMN transcription by 3-fold over the controls.
2.3.4. Targeting DNA methylation
Hauke et al. [32] demonstrated that SMN2 is subject to gene silencing by DNA methylation. In this sense,
inhibition of SMN2 silencing conferred by DNA methylation represents a promising strategy for pharmacologic
SMA therapy. AZA is a potential drug that positively affects SMN protein production by inhibiting methylation
of SMN2 gene transcription factors. Hauke et al. [32] reported on 2-fold increase of SMN protein levels in SMA
patients treated with AZA.
3. Results
3.1. Developing and validating the model
Petri net is some kind of high-level programming language. Petri net software tools usually provide engine with GUI simulator, which in turn converts program code into network of places, transitions, and arcs
similar to the one illustrated in Figure 2. In this work, we use Snoopy [18] framework to create Petri net
model of SMN production network based on four approaches discussed in Section 1 and Subsection 2.3. Our
model comprises 7 discrete places (Dacinostat, TSA, Resveratrol, VPA, AZA, PTMKSMA1 and Indole), 11
continuous places (HDAC_premRNA, HDAC, Methyl, TF_producer, TF, SMN2_gene, SMN2_premRNA,
SMN2_mRNA, SMN2, SMNDelta7mRNA, SMNDelta7), 25 transitions (T1–T19, d1–d6), 2 read, 7 inhibitory,
and 32 regular arcs. Discrete places stand for a drug candidate, while continuous places represent genes and
gene products whose concentration changes smoothly over the time. Treatment by a drug candidate is simulated
by introducing an inhibitory arc directed from discrete place to transition. Treatment by a drug candidate is enabled if discrete place is empty, disabled otherwise. To simulate treatment by a combination of drug candidates,
we keep empty corresponding discrete places. A Boolean variable is used to check absence/presence of a drug
treatment for the drug candidate. In this model, transitions represent transcription, translation, binding, gene
activation, methylation, and degradation processes. Snoopy snapshot of the model is demonstrated in Figure 2.
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To run the application, we simply set the initial data, that is, choose composition of the drug candidates by
placing tokens in corresponding places.
HDAC_premRNA

Methyl

TF

TF_producer
1

T1

T16

T12

T14

SMN2_gene
1

AZA

T9
SMN_Delta7mRNA
d1

T15

T2

d4
Dacinostat

T4

Resveratrol

T6

TSA

T5

T13

SMN2_premRNA

HDAC

T8

d3
SMN_Delta7

T18

T19
PTMKSMA1

d5

T11

T7
SMN2_mRNA

T10

T17
VPA

SMN2

d6

indole

T3

d2

Figure 2. The complete model of SMN production network validated for each of the seven drug candidates that inhibit
HDAC (TSA, VPA, Dacinostat, and Resviratrol), modulate pre-mRNA splicing (PTK-SMA1), upregulate promoter
activity (Indole), and target DNA methylation (AZA). Read arcs and inhibitor arcs are respectively represented by a
black dot and hollow dot as arc head. Read arcs are used to ensure continuous expression of SMN2 gene and production
of transcription factor, while inhibitory arcs are used to simulate enabling/disabling a drug treatment.

We validate the model according to the knowledge derived from biological literature (see Section 1 and
Subsection 2.3), and adjust rates of transitions T7 , T10 , T12 , T13 , T17 , T18 , and T19 in order to strike the balance
between two protein types produced from SMN2, namely 85 percent SMN ∆ 7 and 15 percent SMN. To validate
the model for each of seven drug candidates, we calibrate rates of T3 , T4 , T5 , T6 , T8 , T11 , and T15 one at a
time until reaching desired level of SMN concentration for treatment with specified drug candidate. Rates of
transitions representing mRNA and protein degradations are set to those used in previous works [17, 33]. The
reaction rates are calibrated in terms of stochastic replications by further averaging obtained results.
Once the model is validated, we change kinetic parameter in the hazard function of each transition from
a crisp value b to a fuzzy number (a, b, c). Then we perform 38,000 separate stochastic runs for a, b , and c.
After that, we measure average mean for each parameter with the confidence level of 95% and the accuracy of
10−2 .
3.2. Simulation results
For each of the deterministic, stochastic and fuzzy stochastic models and for each of the 127 drug and drug
combinations we run independent replications and then compute the sample mean to measure SMN concentration. Let Cn be a set of all possible combinations of n drugs for n = 2, . . . , 6, where each c ∈ Cn is recognized
by fuzzy interval, (xc , yc ) . The following algorithm creates a set of effective combinations of n drugs, En .
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algorithm create set of effective drug combinations
input: set of n-combinations, Cn
output: set of effective n-combinations, En
for n:= 2 to 6 do
set En = ∅
remove c with the maximum yc from Cn and add it in En
set ymax = yc and xmin = xc
while En does not contain all effective n -combinations
if yc > ymax then
remove c from Cn and add it in En
ymax = yc
if xc < xmin then xmin = xc
return En

This algorithm splits the set of n -combinations into two disjoint subsets of effective n -combinations
and remaining n -combinations, with the property that the lower limit of any effective n -combination is grater
than the upper limit of any other n -combination for all n . This algorithm allows us to determine a small
set of potentially beneficial drug combinations. Fuzzy intervals of any two effective n -combinations are either
overlapping or one of them contains the other. For instance, this algorithm finds six 3-combinations that span
the interval (16.1, 46) (see Figure 3). Based on the procedure described above, we find that only 35 out of 120
possible n -combinations are effective. All effective n -combinations are represented by Table 1.
16 17

18

19 20

21 22 23

24 25

26 27

28

29 30 31

32 33

34

35 36

37 38

39 40

41 42

43

44

45 46

PTM-SMA1+Indole+VPA
PTM-SMA1+Indole+AZA
PTM-SMA1+Indole+TSA
PTM-SMA1+Dacinostat+AZA
PTM-SMA1+Dacinostat+VPA
PTM-SMA1+AZA+VPA

(16.1, 46)
Figure 3. There are 6 effective 3-combinations out of 35 possible ones. Folds of SMN variation of effective 3-combinations
span the interval (16.1, 46).

According to Table 1, the combination of all seven drug candidates results in the maximum increase of
SMN concentration produced from SMN2 (149.9-fold increase over the control). Although all seven chemicals are
compatible, they can cause serious side effects when used in combination. One important aspect of the present
research is that we determine the scope of effective drug combinations to be examined by pharmacological
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groups. If a drug combination causes unavoidable side effects, there can be still other effective combinations
that can be tested.
We observed that increase in number of drugs does not always result in increase of SMN levels.
For instance, the most effective 5-combination (PTK-SMA1&Dacinostat&Indole&VPA&AZA) yields more
SMN (57.5- to 125.6-fold) than many 6-combinations. Similarly, the most effective 4-combination (PTKSMA1&Dacinostat&AZA&Indole) leads to 40.6- to 88.9-fold increase of SMN levels, which is more than in
case of five effective 5-combinations. It turns out that PTK-SMA1 is the most promising among the seven
chemicals as it is present in all 35 effective combinations, while Indole is present in 23, AZA in 21, Dacinostat
in 20, VPA in 19, TSA in 16, and Resviratrol in 14 effective combinations.
3.2.1. Comparison of deterministic, stochastic and fuzzy stochastic models
Figures 4–6 graphically compare the simulation results for deterministic, stochastic, and fuzzy stochastic models. The solid curves superimposing on the data for the fuzzy stochastic model were obtained by fitting interval
(x, y) in the linear regime. For all n -combinations, both deterministic and stochastic simulations result in
the same most effective drug combination while fuzzy stochastic case in general demonstrates different behavior. For instance, Indole&PTK-SMA1 is the most efficient 2-combination in deterministic and stochastic
models, respectively resulting in 15.03- and 15.367-fold increase of SMN levels. However, it turns out that
PTK-SMA1&Dacinostat is the most efficient in fuzzy stochastic case, leading to 18.2-fold increase of SMN concentration (see Figure 4a). Similarly, deterministic and stochastic models agree that Indole&PTK-SMA1&AZA
is the most efficient 3-combination, respectively resulting in 39,523- and 39.111-fold increase of SMN levels,
with 46-fold over the control group VPA&Indole&PTK-SMA1 is the most efficient in fuzzy stochastic case (see
Figure 4b).
We performed statistical analysis on SPSS Statistics Software Package to characterize more accurately
how much the deterministic, stochastic, and fuzzy stochastic models agree or differ. We conducted normality
tests for all data sets. As a result, neither of these data sets is found to be normally distributed. Thus, we
needed to apply a nonparametric statistical test to pairwise compare corresponding data sets picked up from
distinct models. Appropriate tests are based on the following hypotheses:
H0 : M edian(x) = M edian(y),
H1 : M edian(x) ̸= M edian(y),
where x and y are variables created for deterministic, stochastic, and fuzzy stochastic data sets such that
x ̸= y .
First, Friedman test is conducted to compare the data sets. For all seven drug combinations, Friedman test
resulted in the rejection of the null hypotheses, H0 , with a P < 0.001, which indicates that there is a significant
difference between the medians of data sets determined by the deterministic, stochastic, and fuzzy stochastic
models. Then we performed a paired difference test called the Wilcoxon Signed Rank Test which compares two
related data sets on a single sample to assess whether data sets have the same distribution. Pairwise comparison
of data sets yielded a P-value of < 0.001, which leads us to reject the hypothesis H0 . Hence, we can conclude
that there is an essential difference between distribution of related values in deterministic, stochastic, and fuzzy
stochastic models. Moreover, statistical analysis reveals that values in stochastic case are significantly higher
than corresponding values in deterministic case, and that values in fuzzy stochastic model are substantially
higher compared to related values in stochastic model. Therefore, we conclude that fuzzy stochastic model
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Table. Effective drug combinations determined by deterministic, stochastic, and fuzzy stochastic models.
Effective drug combinations

Model
Deter.

Stoch.

Fuzzy stoch.

PTKSMA1

5.000

5.020

(4.300,7.100)

PTKSMA1&Dacinostat

12.716

13.278

(10.800,18.200)

PTKSMA1&VPA

13.442

14.263

(13.100,17.500)

PTKSMA1&Indole

15.030

15.367

(14.600,17.000)

PTKSMA1&AZA

9.926

11.007

(11.700,12.100)

PTKSMA1&Indole+VPA

35.101

36.522

(30.500,46.000)

PTKSMA1&Indole&AZA

39.523

39.111

(24.000,41.600)

PTKSMA1&Indole&TSA

23.936

25.822

(16.100,32.800)

PTKSMA1&Dacinostat&AZA

23.977

26.689

(23.500,32.900)

PTKSMA1&Dacinostat&VPA

20.621

23.971

(23.300,32.400)

PTKSMA1&AZA&VPA

25.217

28.690

(27.300, 31.900)

PTKSMA1&Dacinostat&AZA&Indole

84.907

64.852

(40.600,88.900)

PTKSMA1&VPA&Indole&AZA

86.877

67.669

(45.800,87.400)

PTKSMA1&Dacinostat&TSA&Indole

40.452

43.963

(27.200,63.800)

PTKSMA1&Dacinostat&Resviratrol&Indole

36.586

39.217

(24.100,55.100)

PTKSMA1&VPA&Resviratrol&Indole

38.095

41.023

(26.400,53.600)

PTKSMA1&Dacinostat&TSA&AZA

29.515

35.135

(22.800,45.700)

PTKSMA1&VPA&AZA&TSA

30.682

36.712

(25.900,44.800)

PTKSMA1&Dacinostat&Indole&VPA&AZA

104.399

86.020

(57.500,125.600)

PTKSMA1&Dacinostat&Indole&AZA&TSA

93.782

75.767

(48.100,110.700)

PTKSMA1&Indole&VPA&AZA&TSA

95.532

77.820

(52.200,108.800)

PTKSMA1&Dacinostat&Indole&Resviratrol&AZA

39.016

39.016

(44.800,99.500)

PTKSMA1&Dacinostat&Indole&VPA&Resviratrol

52.068

56.240

(35.600,82.800)

PTKSMA1&Indole&AZA&Resviratrol&TSA

77.251

60.768

(37.800,79.100)

PTKSMA1&Dacinostat&Indole&TSA&Resviratrol

43.384

48.289

(31.000,70.800)

PTKSMA1&Indole+VPA&Resviratrol&TSA

44.773

49.285

31.700,69.600)

PTKSMA1&Dacinostat&VPA&TSA&AZA

41.874

50.427

PTKSMA1&Dacinostat&VPA&Resviratrol&AZA

39.150

46.747

(32.500,62.000)

PTKSMA1&Dacinostat&Indole&TSA&VPA&AZA

111.086

94.647

(62.900,143.800)

PTKSMA1&Dacinostat&Indole&Resviratrol&VPA&AZA

107.707

90.298

(60.000,133.900)

PTKSMA1&Dacinostat&Indole&Resviratrol&TSA&AZA

97.150

80.664

(51.100,119.400)

PTKSMA1&Indole&Resviratrol&VPA&TSA&AZA

98.842

82.862

(55.500,117.300)

PTKSMA1&Dacinostat&Indole&Resviratrol&VPA&TSA

57.601

63.841

(40.500,97.300)

PTKSMA1&Dacinostat&Resviratrol&VPA&TSA&AZA

43.876

53.701

(37.100,74.400)

7-combination

113.799

98.142

(65.400,149.900)

(38.100,68.400)

is the most adequate model for the case study as this model creates the closest approximation of underlying
biological network.
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15.03 -fold
15.367-fold
39.523 -fold
Folds of SMN variation

Folds of SMN variation

39.111 -fold

18.2-fold
46-fold

b

a

Figure 4. Graphical representation of simulation results for (a) 2-combinations and (b) 3-combinations.

104.399 -fold

86.877 -fold

86.02 -fold
67.669 -fold
Folds of SMN variation

Folds of SMN variation
125.6 -fold
88.9 -fold

a

b

Figure 5. Graphical representation of simulation results for (a) 4-combinations and (b) 5-combinations.
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111.086 -fold

94.647 -fold
Folds of SMN variation

143.8 -fold

Figure 6. Graphical representation of simulation results for 6-combinations.

4. Discussions and further work
A question of practical interest may be the issue of determining precise fuzzy numbers to be assigned to kinetic
parameters with uncertain or unknown experimental values. In [16], the authors adopted the following scheme
for fuzzy parameter estimation: A fuzzy number is initially represented as a union of its α -cuts. The α -cut
for each output is obtained by decomposing all fuzzy parameters into their α -cuts and then running stochastic
simulations at each α level. Following this step, the membership function for each output is obtained by
composing all the α -cuts. Unfortunately, there are some complications preventing the applicability of this
approach in the present work. Firstly, this approach increases the number of simulation runs by the number of
α levels. In the present study, we perform 127 simulation runs for the drugs and their combinations. Application
of the above scheme for even 10 α levels would require 1270 simulation runs and any further decrease in the
step size would result in substantial increase in the number of the simulation runs. Next, the approach suggests
the step size of the α levels be determined carefully according to the nature of the problem, it is not quite clear,
however, how to determine the step size based on the nature of the current case study.
We are aware that medications may have side effects and that, if a medication possesses side effects,
its release, when not required, poses an extra burden on the metabolic system. A combination of multiple
medications may even complicate the situation in the sense that it may cause unexpected side effects. As
further work, in collaboration with pharmacogenetics groups, we propose the in vitro analysis of the current
results to determine the practical applicability of the in silico models in established disease model tissues.
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